Neovascular glaucoma (NVG) has long been recognized as one of the most aggressive forms of secondary glaucoma, but new large-scale data suggest its implications extend well beyond the eye. A multicenter, propensity-matched study, published in Scientific Reports, indicates that NVG is associated with significantly increased long-term mortality and major cardiovascular events – raising the possibility that it could serve as a clinical marker of systemic vascular disease.
Drawing on the TriNetX global electronic health record network, encompassing more than 180 million patients, the study analyzed outcomes in over 17,000 patients with NVG matched 1:1 to cataract controls. The design incorporated extensive adjustment for demographics, comorbidities, medications, and healthcare utilization, with follow-up extending to ten years.
NVG was associated with a 70% increase in all-cause mortality, alongside significantly elevated risks of myocardial infarction, stroke, and cardiac arrest. The research revealed that more than a quarter of NVG patients (26.6%) experienced a three-point major adverse cardiovascular event over 10 years, compared with 15.7% of matched controls.
These associations persisted across multiple sensitivity analyses. When compared with patients with primary open-angle glaucoma (POAG), NVG remained linked to substantially higher mortality and cardiovascular risk, with ten-year mortality nearly doubling (17.1% vs 8.9%). Similarly, among patients with shared underlying conditions such as proliferative diabetic retinopathy (PDR) or retinal vein occlusion (RVO), those who developed NVG experienced worse systemic outcomes than those who did not.
The pathophysiological link is biologically plausible. NVG arises in the context of profound retinal ischemia – most commonly secondary to diabetic retinopathy, retinal vein occlusion, or ocular ischemic syndrome – conditions already associated with systemic microvascular dysfunction. The study authors suggest that ocular neovascularization, driven by VEGF and ischemic signaling, may reflect a broader vascular phenotype affecting multiple organ systems.
Clinically, the findings challenge the traditional view of NVG as a purely ophthalmic complication. Instead, its diagnosis may represent a red flag for systemic risk. As highlighted in the study, NVG could help identify patients at elevated risk of life-threatening cardiovascular events, even after accounting for known comorbidities.
As such, incorporating cardiovascular risk assessment into the management of NVG – potentially through closer collaboration with primary care and cardiology – may offer an opportunity for earlier intervention. Patient counselling may also benefit from reframing NVG not only as a vision-threatening condition, but also as a marker of systemic health.
While the retrospective design and reliance on coded data introduce limitations, the scale and consistency of the findings provide compelling evidence. As imaging technologies such as OCT angiography continue to refine our understanding of ocular ischemia, future studies may further elucidate the mechanistic links between the eye and systemic vascular disease.
In the meantime, this study underscores a broader message: in NVG, the stakes may extend far beyond vision.
